Haemonetics Financials
HAE Stock | USD 88.53 0.07 0.08% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.34 | 0.8415 |
|
| |||||
Current Ratio | 1.35 | 2.5597 |
|
|
The financial analysis of Haemonetics is a critical element in measuring its lifeblood. Investors should not minimize Haemonetics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Cash And Equivalents |
|
Haemonetics | Select Account or Indicator |
Understanding current and past Haemonetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Haemonetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Haemonetics' assets may result in an increase in income on the income statement.
Haemonetics Earnings Geography
Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.
Haemonetics Stock Summary
Haemonetics competes with Merit Medical, AngioDynamics, AptarGroup, Envista Holdings, and Hologic. Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | New York Stock Exchange |
ISIN | US4050241003 |
CUSIP | 405024100 |
Location | Massachusetts; U.S.A |
Business Address | 125 Summer Street, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.haemonetics.com |
Phone | 781 848 7100 |
Currency | USD - US Dollar |
Haemonetics Key Financial Ratios
Return On Equity | 0.14 | ||||
Profit Margin | 0.09 % | ||||
Operating Margin | 0.16 % | ||||
Price To Sales | 3.24 X | ||||
Revenue | 1.31 B |
Haemonetics Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.3B | 1.8B | 1.9B | 1.9B | 2.2B | 2.3B | |
Other Current Liab | 127.7M | 128.5M | 116.8M | 145.9M | 185.6M | 194.8M | |
Net Debt | 245.2M | 515.3M | 514.1M | 481.4M | 629.0M | 660.4M | |
Retained Earnings | 78.5M | 158.0M | 202.4M | 253.2M | 360.5M | 281.9M | |
Accounts Payable | 50.7M | 50.3M | 58.4M | 63.9M | 73.4M | 77.0M | |
Cash | 137.3M | 192.3M | 259.5M | 284.5M | 178.8M | 138.4M | |
Net Receivables | 165.2M | 127.6M | 159.4M | 179.1M | 206.6M | 120.7M | |
Inventory | 270.3M | 322.6M | 293.0M | 259.4M | 317.2M | 333.1M | |
Other Current Assets | 30.8M | 102.1M | 88.3M | 46.7M | 66.3M | 40.1M | |
Total Liab | 680.0M | 1.1B | 1.1B | 1.1B | 1.2B | 1.3B | |
Total Current Assets | 603.6M | 693.5M | 756.0M | 769.7M | 768.9M | 437.2M | |
Short Term Debt | 77.0M | 24.7M | 221.3M | 11.8M | 10.2M | 9.7M | |
Intangible Assets | 133.1M | 365.5M | 310.3M | 275.8M | 406.1M | 426.4M | |
Other Liab | 48.7M | 38.2M | 76.9M | 108.6M | 124.9M | 131.1M | |
Other Assets | 14.1M | 17.0M | 67.7M | 58.8M | 1.0 | 0.95 | |
Long Term Debt | 305.5M | 690.6M | 559.4M | 754.1M | 797.6M | 837.4M | |
Good Will | 210.7M | 466.4M | 467.3M | 466.2M | 565.1M | 593.3M | |
Net Tangible Assets | 243.4M | (100.3M) | (28.1M) | 76.0M | 68.4M | 65.0M | |
Long Term Debt Total | 305.5M | 690.6M | 559.4M | 754.1M | 867.2M | 910.6M | |
Capital Surpluse | 553.2M | 602.7M | 572.5M | 594.7M | 683.9M | 516.6M |
Haemonetics Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 16.2M | 16.8M | 17.1M | 14.6M | 13.0M | 15.4M | |
Total Revenue | 988.5M | 870.5M | 993.2M | 1.2B | 1.3B | 1.4B | |
Gross Profit | 484.5M | 397.8M | 505.5M | 615.1M | 691.5M | 726.1M | |
Operating Income | 154.0M | 58.0M | 80.8M | 156.0M | 164.9M | 173.1M | |
Ebit | 154.0M | 58.0M | 80.8M | 156.0M | 168.4M | 176.8M | |
Ebitda | 264.2M | 142.3M | 178.5M | 249.3M | 265.6M | 278.9M | |
Cost Of Revenue | 504.0M | 472.6M | 487.7M | 553.6M | 617.5M | 329.8M | |
Income Before Tax | 87.2M | 72.9M | 63.6M | 141.4M | 151.9M | 159.5M | |
Net Income | 76.5M | 79.5M | 43.4M | 115.4M | 117.6M | 123.4M | |
Income Tax Expense | 10.6M | (6.6M) | 20.3M | 26.0M | 34.3M | 17.5M | |
Research Development | 30.9M | 32.9M | 46.8M | 50.1M | 54.4M | 33.3M | |
Tax Provision | 10.6M | (6.6M) | 20.3M | 26.0M | 34.3M | 36.0M | |
Interest Income | 16.2M | 16.8M | 17.1M | 14.6M | 16.8M | 13.3M | |
Net Interest Income | (16.2M) | (16.8M) | (17.1M) | (14.6M) | (13.0M) | (13.7M) |
Haemonetics Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (84.7M) | (38.9M) | 24.3M | 30.8M | (60.1M) | (57.1M) | |
Change In Cash | (32.0M) | 55.0M | 67.2M | 25.0M | (105.7M) | (100.4M) | |
Free Cash Flow | 109.5M | 71.8M | 75.8M | 162.9M | 115.5M | 121.2M | |
Depreciation | 110.3M | 84.3M | 97.7M | 93.3M | 97.2M | 54.3M | |
Other Non Cash Items | 42.5M | (919K) | 16.9M | 8.5M | 24.4M | 20.1M | |
Capital Expenditures | 48.8M | 37.0M | 96.5M | 110.2M | 66.3M | 54.3M | |
Net Income | 76.5M | 79.5M | 43.4M | 115.4M | 117.6M | 123.4M | |
End Period Cash Flow | 137.3M | 192.3M | 259.5M | 284.5M | 178.8M | 138.4M | |
Change To Netincome | 64.0M | 4.7M | 46.3M | 36.2M | 41.6M | 40.4M | |
Change Receivables | 18.9M | 44.1M | (35.0M) | (24.4M) | (28.1M) | (26.7M) | |
Net Borrowings | 31.9M | 370.7M | (17.5M) | 269.3M | 309.6M | 325.1M | |
Investments | (57.2M) | (425.4M) | (86.3M) | (143.8M) | (322.4M) | (306.3M) |
Haemonetics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Haemonetics's current stock value. Our valuation model uses many indicators to compare Haemonetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Haemonetics competition to find correlations between indicators driving Haemonetics's intrinsic value. More Info.Haemonetics is rated # 3 in return on equity category among its peers. It is rated # 4 in return on asset category among its peers reporting about 0.42 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Haemonetics is roughly 2.38 . At present, Haemonetics' Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Haemonetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Haemonetics Systematic Risk
Haemonetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Haemonetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Haemonetics correlated with the market. If Beta is less than 0 Haemonetics generally moves in the opposite direction as compared to the market. If Haemonetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Haemonetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Haemonetics is generally in the same direction as the market. If Beta > 1 Haemonetics moves generally in the same direction as, but more than the movement of the benchmark.
Haemonetics Thematic Clasifications
Haemonetics is part of several thematic ideas from Baby Boomer Prospects to Obamacare Repeal. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasToday, most investors in Haemonetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Haemonetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Haemonetics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Haemonetics November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Haemonetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Haemonetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Haemonetics based on widely used predictive technical indicators. In general, we focus on analyzing Haemonetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Haemonetics's daily price indicators and compare them against related drivers.
Downside Deviation | 1.51 | |||
Information Ratio | 0.0545 | |||
Maximum Drawdown | 14.5 | |||
Value At Risk | (2.10) | |||
Potential Upside | 4.24 |
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |